GLP-1RA在2型糖尿病中的应用进展  

Application Progress of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus

作　　者：崔佳乐 杨艳[1] 彭雅茗 周广举[1] CUI Jiale;YANG Yan;PENG Yaming;ZHOU Guangju(Department of Endocrinology,Affiliated Hospital of North Sichuan Medical College,Nanchong 637000,China)

机构地区：[1]川北医学院附属医院内分泌科,四川南充637000

出　　处：《医学综述》2021年第4期778-782,787,共6页Medical Recapitulate

摘　　要：胰岛素抵抗、胰岛β细胞功能衰竭、胰高血糖素分泌异常是2型糖尿病(T2DM)的主要发病机制。胰高血糖素样肽-1(GLP-1)是一种具有多种药理作用的内分泌激素,具有抑制胰岛β细胞凋亡、促进胰岛素分泌、减少食物摄取、延缓胃排空、增强外周组织的葡萄糖利用以及减少肝糖输出等作用,但易被二肽基肽酶-Ⅳ降解。而GLP-1受体激动剂(GLP-1RA)可有效弥补这一缺点,延长GLP-1半衰期,因此可用于T2DM的治疗。GLP-1RA在T2DM患者中显示了较好的治疗潜力,且未引起低血糖和体重增加等不良反应。另外,GLP-1RA对T2DM合并心血管疾病患者也有显著的治疗益处。Insulin resistance,isletβ-cell failure and abnormal glucagon secretion are the main pathogenesis of type 2 diabetes mellitus(T2DM).Glucagon-like peptide-1(GLP-1)is an endocrine hormone with multiple pharmacological effects,which can inhibit isletβ-cell apoptosis,promote insulin secretion,reduce food intake,delay gastric emptying,enhance peripheral tissue glucose utilization and reduce liver glucose output,but it can be easily degraded by dipeptidyl peptidase-IV.GLP-1 receptor agonist(GLP-1RA)can effectively make up for this deficiency and prolong the half-life of GLP-1,so it can be used in the treatment of T2DM.GLP-1RA has shown good treatment potential in patients with T2DM without causing adverse reactions such as hypoglycemia and weight gain.In addition,GLP-1RA also has significant therapeutic benefits for patients with T2DM complicated with cardiovascular disease.

关 键 词：2型糖尿病 胰高血糖素样肽-1 胰高血糖素样肽-1受体激动剂 

分 类 号：R587.1[医药卫生—内分泌]